Andere Sprachen Denali Therapeutics Inc.

Aktien

A2H9G8

US24823R1059

DNLI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
15,43 ^USD	+3,14 %		-3,56 %	-28,10 %

09.04.	DENALI THERAPEUTICS INC. : erhält Kaufen-Rating von UBS	ZM
03.04.	Denali Therapeutics Insider verkaufte Aktien im Wert von $1.896.250, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03.04.
Denali Therapeutics Files Prospectus for Secondary Offering	22.03.
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	01.03.
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	27.02.
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	27.02.
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27.02.
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27.02.
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27.02.
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27.02.
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	27.02.
North American Morning Briefing : S&P 500 Futures -2-	23.02.
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	20.02.
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	16.02.
Sanofi : échec d'un essai de phase 2 contre la SLA	16.02.
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	16.02.
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07.02.
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07.02.
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	07.02.
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Denali Therapeutics Inc.

Aktien

A2H9G8

US24823R1059

DNLI

Andere Sprachen

Filter